Search
Now showing items 41-50 of 171
Current Advances in CAR T Cell Therapy for Malignant Mesothelioma.
(Scientific Archives LLC, 2020-06-22)
Malignant mesothelioma is a relatively rare malignancy arising in the body's serosal surfaces, with malignant pleural mesothelioma (MPM) being the most common type. It is characterized by local spread within the thorax, ...
Mesothelin-targeted CAR-T cell therapy for solid tumors.
(TAYLOR & FRANCIS LTD, 2021-04-03)
Introduction: Mesothelin (MSLN) is a tumor differentiation antigen normally restricted to the body's mesothelial surfaces, but significantly overexpressed in a broad range of solid tumors. For this reason, MSLN has emerged ...
Peritumoral Delivery of Docetaxel-TIPS Microparticles for Prostate Cancer Adjuvant Therapy.
(WILEY, 2020-10-19)
Recurrence of prostate cancer after radical prostatectomy is a consequence of incomplete tumor resection. Systemic chemotherapy after surgery is associated with significant toxicity. Improved delivery methods for toxic ...
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
(ELSEVIER, 2020-11-08)
BACKGROUND: Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond. OBJECTIVE: To characterise ATM-deficient ...
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network.
(SPRINGERNATURE, 2020-08-19)
Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased risk of infections ...
Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model.
(CELL PRESS, 2020-09-25)
The therapeutic efficacy of adoptive transfer of T cells transduced with chimeric antigen receptors (CARs) has been limited in the treatment of solid cancers, partly due to tumor antigen heterogeneity. Overcoming lack of ...
Hypoxia and its therapeutic possibilities in paediatric cancers.
(SPRINGERNATURE, 2021-02-02)
In tumours, hypoxia-a condition in which the demand for oxygen is higher than its availability-is well known to be associated with reduced sensitivity to radiotherapy and chemotherapy, and with immunosuppression. The ...
Immunomodulatory activity of IR700-labelled affibody targeting HER2.
(SPRINGERNATURE, 2020-10-20)
There is an urgent need to develop therapeutic approaches that can increase the response rate to immuno-oncology agents. Photoimmunotherapy has recently been shown to generate anti-tumour immunological responses by releasing ...
Unconventional role of RAC1 in MET-driven anchorage-independent tumor growth.
(TAYLOR & FRANCIS INC, 2020-08-18)
We reported that RAC1 is a master regulator of cell migration and anchorage-independent growth, downstream of the oncogenic Receptor Tyrosine Kinase (RTK) MET. RAC1 growth-promoting role is guanosine triphosphatase (GTPase)- ...
The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial.
(NATURE PUBLISHING GROUP, 2020-02-01)
Disease factors such as tumor burden and molecular risk affect myeloma patient outcomes as well as patient factors that impact the capacity to deliver treatment. How the relative importance of these factors changes with ...